Core Insights - China National Pharmaceutical Group Corporation (referred to as "the company") reported a revenue of 17.076 billion yuan for the first half of 2025, representing a year-on-year decline of 6.71% [1] - The company's net profit attributable to shareholders was 294 million yuan, down 16.19% year-on-year [1] Business Transformation and Innovation - The company has been focusing on business transformation and innovation, enhancing market development and accelerating product introduction [1] - Significant progress was made in optimizing production processes for key raw materials, with effective improvements in technical indicators [1] - The company has initiated 12 industrial projects, submitted 10 for approval, and received approval for 10, along with filing 17 invention patent applications [1] International Business Growth - The company has continued to promote localized compliance operations in overseas markets, with revenue growth of 50% in Latin America and Central Asia, and substantial growth in the North African market [1] - Progress in traditional Chinese medicine diagnosis and treatment projects has been smooth [1] E-commerce and Health Sector Development - The new health and e-commerce business segments have started robustly, achieving a sales increase of 30% during the "618" shopping festival, setting a new historical high [1] - The company established a health and e-commerce division to systematically integrate e-commerce resources within the organization [1] Management and Operational Efficiency - The company's management foundation has been continuously strengthened, with improved control efficiency supporting compliant and effective operations [1]